Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decamethonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.92 |
| ▸ | ACHE | P22303 | 3/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.92 |
| ▸ | LMNA | P02545 | 2/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.92 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.92 |
| ▸ | TSHR | P16473 | 1/20 | 0.92 |
| ▸ | RAB9A | P51151 | 1/20 | 0.92 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.75 |
| ▸ | APAF1 | O14727 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | RAD52 | P43351 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decamethonium SCHEMBL2830377 | 1.00 | APEX1 (1.00) | APEX1NPSR1MEN1KMT2AACHE | |
| Pentamethonium SCHEMBL8914783 | 1.00 | APEX1 (1.00) | APEX1NPSR1MEN1KMT2AACHE | |
| Hydrochloric Acid SCHEMBL6012972 | 1.00 | APEX1 (1.00) | APEX1NPSR1MEN1KMT2AACHE | |
| Hydrochloric Acid SCHEMBL6012951 | 1.00 | APEX1 (1.00) | APEX1NPSR1MEN1KMT2AACHE | |
| Decamethonium SCHEMBL2831663 | 1.00 | APEX1 (1.00) | APEX1NPSR1MEN1KMT2AACHE | |
| Hydrochloric Acid SCHEMBL3679398 | 1.00 | APEX1 (1.00) | APEX1NPSR1MEN1KMT2AACHE | |
| Hexamethonium SCHEMBL22332 | 1.00 | APEX1 (1.00) | APEX1NPSR1MEN1KMT2AACHE | |
| Hexamethonium SCHEMBL1338459 | 0.96 | APEX1 (0.92) | APEX1NPSR1MEN1KMT2AACHE | |
| SCHEMBL6931794 | 0.96 | MEN1 (1.00) | APEX1NPSR1MEN1KMT2AACHE | |
| SCHEMBL17898630 | 0.96 | MEN1 (1.00) | APEX1NPSR1MEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117511000-A | Anti-adhesion agent and breeding colony house modifier comprising same | 成都科宏达科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2023228116-A1 | INTRANASAL ADMINISTRATION OF THERMOSTABLE RNA VACCINES | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2023-11-30 | — | — | WO | claimed |
| EP-1005651-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-06-07 | — | — | EP | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |
| US-4064232-A | Process for isolating the immunogenic components of influenza viruses | SANDOZ LTD. (CH) | 1977-12-20 | — | — | US | claimed |
| CN-117511000-B | Anti-adhesion agent and breeding colony house modifier comprising same | 成都科宏达科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260076881-A1 | ARAGONITE COMPOSITIONS, METHODS, AND USES THEREOF | NANT HOLDINGS IP, LLC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034230-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260014185-A1 | Delivery of RNA to Different Cell Types | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-01-15 | — | — | US | disclosed |
| US-20260007738-A1 | SELF-REPLICATING RNA VACCINES AND METHODS OF USE | Immorna (hangzhou) Biotechnology Co., Ltd. (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12514796-B2 | Aragonite compositions, methods, and uses thereof | NANT HOLDINGS IP, LLC (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4662312-A1 | METHODS AND MODIFICATIONS FOR REDUCING INNATE IMMUNE RESPONSES TO RNA | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-0170053-B1 | QUATERNARY AMMONIUM SALTS OF CARBOXYMETHYLCELLULOSE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0447551-A1 | STABILIZATION OF COMPOSITION CONTAINING ANIONIC SURFACTANT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-4617385-A | THICKENERS, ANTISTATIC AGENTS | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1986-10-14 | — | — | US | disclosed |
| EP-0007758-B1 | ALKYL AMMONIUM IONOMERS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1983-03-30 | — | — | EP | disclosed |
| EP-0007758-A1 | Alkyl ammonium ionomers | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1980-02-06 | — | — | EP | disclosed |
| US-4173695-A | THICKENERS, ADHESIVES, THERMOPLASTIC ELASTOMERS | EXXON RESEARCH & ENGINEERING CO. (US) | 1979-11-06 | — | — | US | disclosed |
| US-4140762-A | HEMAGGLUTININ AND NEURAMINIDASE COMPONENTS OF VIRUS | SANDOZ LTD. (CH) | 1979-02-20 | — | — | US | disclosed |
| US-4064232-A | Process for isolating the immunogenic components of influenza viruses | SANDOZ LTD. (CH) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034230-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | MUSK, TFRC, MYOF | APEX1 4336/4885NPSR1 1579/4885MEN1 3924/4885 |
| US-20260076881-A1 | ARAGONITE COMPOSITIONS, METHODS, AND USES THEREOF | ORAI1, CA2, CACNA2D1 | APEX1 3979/4885NPSR1 1732/4885MEN1 1618/4885 |
| US-20260007738-A1 | SELF-REPLICATING RNA VACCINES AND METHODS OF USE | RNMT, RNGTT, NSUN2 | APEX1 1891/4885NPSR1 3797/4885MEN1 3104/4885 |
| US-20260014185-A1 | Delivery of RNA to Different Cell Types | NUP205, NSUN3, NPC1 | APEX1 978/4885NPSR1 2537/4885MEN1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.